Q1 2025 Niagen Bioscience Inc Earnings Call Transcript
Key Points
- Niagen Bioscience Inc (NAGE) reported a 38% year-over-year increase in revenue, reaching $30.5 million for the first quarter of 2025.
- The company achieved a net income of $5.1 million, marking the third consecutive quarter of profitability.
- E-commerce sales grew by 31% year-over-year, contributing significantly to the company's revenue growth.
- The Niagen ingredient business saw a 95% increase, with food-grade and pharmaceutical-grade sales reaching $8 million.
- The company ended the quarter with $55.6 million in cash and no debt, providing significant financial flexibility.
- The market for NAD supplements is crowded, with many competitors making unverified claims, posing a challenge for Niagen Bioscience Inc (NAGE) to differentiate its products.
- The FDA's ruling against NMN as a dietary ingredient could impact market perceptions and regulatory challenges for similar products.
- The company's marketing expenses, while efficient, are expected to increase, potentially impacting profit margins.
- The pharmaceutical-grade Niagen supply chain is complex and heavily regulated, which has previously led to supply challenges.
- The results of the Phase III NO-PARK study for Parkinson's disease will not be available for several months, delaying potential market impact.
Ladies and gentlemen, thank you for standing by, and welcome to Niagen Biosciences, Inc.'s first quarter of 2025 earnings conference call. My name is Kayla, and I will be the conference operator today. (Operator Instructions) And as a reminder, this conference call is being recorded.
This afternoon, Niagen Bioscience issued a news release announcing the company's financial results for the First Quarter of 2025. If you have not reviewed this information, both are available within the Investor Relations section of Niagen Bioscience's website at www.niagenbioscience.com.
I would now like to turn the conference call over to Wesley Yu, Vice President of Finance. Please go ahead, Mr. Yu.
Thank you. Good afternoon, and welcome to Niagen Biosciences First Quarter of 2025 Conference Call. With us today are Niagen Bioscience's Chief Executive Officer, Rob Fried; Chief Financial Officer, Ozan Pamir; and Senior Vice
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
